Loading...
Loading...
IMUX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 27.3M |
| Operating I/L | -27.3M |
| Other Income/Expense | 2.0M |
| Interest Income | 0.8M |
| Pretax | -25.3M |
| Income Tax Expense | -2.0M |
| Net Income/Loss | -23.3M |
Immunic, Inc. is a clinical-stage biopharmaceutical company specializing in the development of selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company's lead program, IMU-838, is in Phase 2 clinical trials for the treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, including coronavirus disease. Additionally, Immunic is developing IMU-935, an inverse agonist of ROR?t, and IMU-856 for restoring intestinal barrier function in patients with various intestinal barrier function diseases.
